Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Date:11/3/2008

and in those undergoing major orthopedic surgery, treatment and secondary prevention of VTE, and acute coronary syndromes (ACS).

About Atrial Fibrillation

Atrial fibrillation (AF) is a major cause of hospitalization and mortality and affects about 2.5 million people in the United States, as well as 4.5 million people in the European Union and is emerging as a growing public health concern due to an aging population. In atrial fibrillation, some blood inside the atria may stagnate, and clots may form. If a piece of the clot breaks off and subsequently blocks an artery in the brain, a stroke results. According to the joint ACC/AHA/ESC guidelines for the management of atrial fibrillation, patients with atrial fibrillation have a two- to seven-fold increased risk of stroke and also have an increased risk of death and cardiovascular complications, including myocardial infarction.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development, addressing the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry and kinase expertise to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases with broader activity. The company also has a novel anticoagulant antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/16/2014)... September 16, 2014 RENU 28, the world's ... became available for purchase in Australia and New Zealand ... tour beginning September 16th. The tour will make stops in ... Bundaberg on the 18th, Sydney on the 20th, and Melbourne ... Australia and New Zealand and to educate people about the ...
(Date:9/15/2014)... UPTON, NYHeat drives classical phase transitionsthink solid, ... happen when the temperature drops. If phase ... where quantum mechanics reigns, subtle fluctuations can ... from the U.S. Department of Energy,s Brookhaven ... explored this frigid landscape of absolute zero ...
(Date:9/15/2014)... 2014   Global Science & Technology, Inc. ... and services for satellite and weather systems, was ... Services (OASIS) from the General Services Administration (GSA) ... provide the government best-value solutions for complex professional ... in Pool 4. The OASIS SB award has ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTC Bulletin Board: ... 7,850,970, entitled "Inhibitors of Serine Protease Activity and Their Use ... issued by the United States Patent and Trademark Office (USPTO) ... New Patent is part of the technology licensed to Omni ...
... new method of child and maternal nutrition could prevent a ... up to 160 million brain cells in each person over ... related to aging and cancer. Most people are ... contaminated with a radioactive material from the air known as ...
... YORK, Jan. 4, 2011 Reportlinker.com announces ... available in its catalogue: ... Strategies for Suppliers,>The 2011 Coagulation Testing Market: ... Market Expansion Strategies for Suppliers ...
Cached Biology Technology:Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection 2Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection 3New Method of Nutrition to Permanently Protect Brain Cells from Genetic Damage 2Reportlinker Adds The 2011 Coagulation Testing Market: US, Europe, Japan Emerging Business Opportunities and Market Expansion Strategies for Suppliers 2
(Date:9/15/2014)... leading coral reef ecologists fears that reef biodiversity may ... that we once thought. , In an international study ... of Excellence for Coral Reef Studies (Coral CoE) says ... species within reef ecosystems. , In coral reefs, just ... that keep the ecosystem safe and functioning. , ...
(Date:9/15/2014)... for the first 500 million years after it formed ... complete with oceans, continents and active crustal plates. , ... the Hadean, has gained substantial new support from the ... than 4 billion years ago with those formed contemporaneously ... geological analog for early Earth. , The study was ...
(Date:9/15/2014)... transplanted combinations of wild, domesticated, and domesticated-wild ... new environments found that within 5 to ... genes from wild populations that hybridized with ... study provides evidence that natural selection, ... hybridized populations experience as a result of ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... a half-dozen palladium- and iron-based catalysts for cleaning up the ... TCE far faster than iron -- up to a billion ... in a new study in the August issue of the ... trichloroethene, is a widely used chemical degreaser and solvent that,s ...
... Six, the world leader in synthetic diamond supermaterials, ... Departments of Chemistry and Physics, have demonstrated the ... metal-like boron-doped synthetic diamond. The research shows that ... retaining the full strength and durability of its ...
... NANG, VietnamU.S. scientists and Vietnamese researchers will discuss coastal ... the R/V Roger Revelle , an auxiliary general ... port call in the city of Da Nang. ... operated by the Scripps Institution of Oceanography, the advanced ...
Cached Biology News:Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 2Synthetic diamond steps closer to next generation of high performance electrochemical applications 3US research vessel winds down visit to Vietnam as part of joint oceanographic research program 2
ANTI ALPHA FSH:B...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Normal donkey serum collected from healthy normal donkeys....
acridine orange 10-nonyl bromide (nonyl acridine orange)...
Biology Products: